Michael Shi
Victoria University(AU)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Renal cell carcinoma treatment, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets(2012)638 cited
- → Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer(2013)312 cited
- → Quinone-induced oxidative stress elevates glutathione and induces gamma-glutamylcysteine synthetase activity in rat lung epithelial L2 cells(1994)308 cited
- → Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies(2001)287 cited
- → Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial(2014)263 cited
- → γ-Glutamyl Transpeptidase is Increased by Oxidative Stress in Rat Alveolar L2 Epithelial Cells(1994)162 cited
- → Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis(2000)156 cited
- → Molecular Cloning and Characterization of DEFCAP-L and -S, Two Isoforms of a Novel Member of the Mammalian Ced-4 Family of Apoptosis Proteins(2001)147 cited
- → Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy(2011)131 cited
- → Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma(2013)130 cited